Table 3.
Ref. | No. of patients |
Neoadjuvant therapy regimen |
No. of LR |
||
Radiotherapy (Gy) | Chemotherapy | pCR LR/total | Non-pCR LR/total | ||
Gavioli et al[31] | 139 | 50 | 5-Fu | 0/25 (0.0) | 8/114 (7.0) |
Stipa et al[57] | 200 | 50 | 5-Fu | 0/60 (0.0) | 6/140 (4.3) |
Hughes et al[71] | 130 | 45 | 5-Fu | 0/23 (0.0) | 23/107 (17.7) |
Kim et al[82] | 114 | 50.4 | 5-Fu | 0/10 (0.0) | 17/104 (16.3) |
Kuo et al[83] | 248 | 50 | 5-Fu | 2/36 (5.6) | 66/212 (31.1) |
Chan et al[84] | 128 | 50 | 5-Fu | 0/32 (0.0) | 24/96 (18.4) |
García-Aguilar et al[86] | 168 | 40-65 | 5-Fu | 0/21 (0.0) | 7/147 (5) |
Wheeler et al[87] | 63 | 45-50 | 5-Fu | 1/29 (3.4) | 8/34 (23.5) |
Theodoropoulos et al[88] | 88 | 45 | 5-Fu | 0/16 (0.0) | 3/72 (4.2) |
Total | 1278 | 3/252 (1.2) | 162/1026 (15.8) |
LR: Local recurrence; pCR: Pathologic complete remission; 5-Fu: 5-fluorouracil.